SARS-CoV-2 infection and vaccination in patients with pituitary diseases: the experience of a Brazilian reference center.

Marcela Cunha da SilvaSolena Ziemer Kusma FidalskiCesar Luiz Boguszewski

Published in: Pituitary (2024)

The prevalence of SARS-CoV-2 infection in our cohort was 35.2%, including 14% of moderate and severe cases requiring hospitalization. The vaccination was universal and safe.

Keyphrases

respiratory syndrome coronavirus
risk factors
early onset
coronavirus disease